Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

ncluding a SELENA/SLEDAI** improvement of 5 points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two or more new BILAG B organ domain scores.

About Blisibimod and PEARL-SCBAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging superiority trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide.About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan,
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014  Eli Lilly and ... results from its non-clinical study in genetically engineered ... of the beta-amyloid antibody N3pG and beta-secretase inhibitor ... was more effective in removing clumps of amyloid-beta ... is thought to lead to Alzheimer,s disease (AD) ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... Israel, November 12 Surgeons,at the University of ... can be converted to an endovascular simulator,(ANGIO Mentor(TM), ... agreed" that the simulation improved the operative flow,increased ... operative and fluoroscopy time and the amount of ...
... New Data Suggesting Need for Improved ... Annual Meeting -, EXTON, Pa., Nov. 12 ViroPharma ... from its ongoing,open-label study, showing that in this study Cinryze(TM) ... (HAE),attacks seen in the study through the date of analysis. ...
Cached Medicine Technology:Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6
(Date:7/13/2014)... The report “Micronutrient Market by ... (Chelated & Non Chelated), Application Mode (Soil, Foliar, ... and Forecast to 2018” defines and segments the ... forecasting of the global value and volume for ... restraining factors for the global agriculture micronutrients market ...
(Date:7/13/2014)... 13, 2014 A Massachusetts couple who ... cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... to federal regulators, as they presented poignant testimony on ... Drug Administration (FDA) advisory panel meeting convened to address ... the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... imaging device developed at Cedars-Sinai can provide early ... brain and are a classic sign of Alzheimer,s ... a clinical trial in Australia. , The researchers ... oral presentation at the Alzheimer,s Association International Conference ... by conference organizers to participate in a "breaking ...
(Date:7/13/2014)... 13, 2014 Celebrity fitness trainer and ... a promotional partnership with Aqua Health Labs for their ... EPA supplement . The collaboration was recently announced live ... fitness trainer , actor, model, and a two time ... A-List celebrities, he has prepared stars including Demi Moore, ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... states, CDC report shows, , TUESDAY, March 2 (HealthDay ... States, a new government study shows, but certain states ... The overall rate of asthma is currently estimated to ... about 0.5 percent every three years. But, the report ...
... , ... ... ... ...
... , ... ... ... ...
... ... ... , ... , , , ...
... ... into the exploding field of neuroscience, what this means for leadership and how it ... to motivate and generate transformation in organisations – all leading to better organisations and ... ...
... ... Software Developers. , ... RSA San Francisco, CA (PRWEB) March 2, 2010 -- GlobalSign Inc ... in supplying Digital Identities used to authenticate the publisher of software and produce ...
Cached Medicine News:Health News:Asthma Rates Rising Across the U.S. 2Health News:Asthma Rates Rising Across the U.S. 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 2Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 4Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 5Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 6Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 7Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 8Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 9Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 2Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 3Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 4Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 5Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 6Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 7Health News:InterAmerican College Announces Certification of Master of Science in Nursing - Family Nurse Practitioner Program 2Health News:InterAmerican College Announces Certification of Master of Science in Nursing - Family Nurse Practitioner Program 3Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:GlobalSign Releases Code Signing Certificates for Individual Software Developers 2Health News:GlobalSign Releases Code Signing Certificates for Individual Software Developers 3
The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
The 14D provides high magnification along with an optimized working distance from the cornea. With its 4.30x magnification, it is also well suited for optic disc and macular observation....
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
Medicine Products: